Roivant Q1 Fiscal 2027 Update Confirms Lisraya Launch Team, Distribution, and Payer Coverage as U.S. Commercial Launch Begins August 28
Alongside the FDA approval announcement Wednesday August 27, 2026, Roivant Sciences (NASDAQ: ROIV) filed an 8-K disclosure and hosted a conference call Friday August 28, 2026 confirming that Priovant Therapeutics has fielded a dermatology-and-rheumatology-focused sales force, contracted with major specialty pharmacy distributors, and secured initial payer coverage sufficient to begin U.S. commercial launch on August 28. Priovant is a Pfizer-Roivant joint venture (Roivant 75%, Pfizer 25%) that was created in 2022 specifically to advance brepocitinib in dermatomyositis, cutaneous lupus, and non-infectious uveitis. Beyond Lisraya, Priovant's brepocitinib program continues in Phase 3 for cutaneous lupus (VALIANT) with topline data expected in H1 2027 and in Phase 2 for non-infectious uveitis. The launch is a signal event for the Roivant 'Vant' model, in which spin-out subsidiaries develop and commercialize discrete assets while remaining consolidated within the parent. Not a peptide; included because the JAK/TYK2 inhibitor category continues to displace older peptide-based immunomodulation approaches in autoimmune disease.